Biotech and Pharmaceuticals Pharmaceuticals

More

  • Revenue rose 8.6 percent to $5.4 billion in the second quarter, topping Wall Street estimates of $5.15 billion, as demand increased for its drugs including Trulicity, Cyramza and Humalog. The 140- year-old U.S. drugmaker said its net income rose 24.5 percent to $747.7 million, or 71 cents per share, in the quarter ended June 30. Excluding special items, Lilly earned...

  • July 26- Eli Lilly and Co reported a 24.5 percent jump in quarterly profit, driven by demand for its newer treatments for diabetes and cancer. The 140- year-old U.S. drugmaker said its net income rose to $747.7 million, or 71 cents per share, in the second quarter ended June 30, from $600.8 million, or 56 cents per share, a year earlier. Revenue rose 8.6 percent to $5.4...

  • TOKYO, July 26- Takeda Pharmaceutical Co Ltd will accept initial bids for its 70 percent stake in a chemicals company through Aug. 16, with potential suitors including CVC Capital Partners Ltd and Carlyle Group Ltd, sources told Reuters. Takeda, Japan's largest drugmaker by market value, aims to sell its holding in Wako Pure Chemicals Industries Ltd to streamline...

  • LITTLE ROCK, Ark.— An execution drug obtained by the Arkansas prison system earlier this month appears to have been made by a subsidiary of Pfizer, even though the pharmaceutical giant has said it doesn't want its drugs to be used in executions. It matches labels submitted to the National Institutes of Health by Hospira, Inc., which Pfizer bought last year.

  • Active Ownership Capital, which controls a stake of around 7 percent in Stada, wants to oust chairman Martin Abend and install international pharmaceutical experts at the company's annual general meeting on Aug. 26. In a statement on Monday, Active Ownership said it opposed current members Martin Abend, Carl Ferdinand Oetker and two prospective new members,...

  • Active Ownership Capital, which controls a stake of around 7 percent in Stada, wants to oust chairman Martin Abend and install international pharmaceutical experts at the company's annual general meeting on August 26.

  • Yee: Biotech stocks will outperform after election

    Les Funtleyder, E Squared asset management, and Michael Yee, RBC biotech analyst, discuss trading health care and the future of biotech during the election.

  • Bracing for a 'bio-wreck'?

    Though the biotech sector has had a sharp turnaround since mid June, is the worst really over? The "Fast Time Halftime Report" traders discuss whether or not its worth buying the biotech bounce.

  • WASHINGTON— A safeguard for Medicare beneficiaries has become a way for drugmakers to get paid billions of dollars for pricey medications at taxpayer expense, government numbers show. The cost of Medicare's "catastrophic" prescription coverage jumped by 85 percent in three years, from $27.7 billion in 2013 to $51.3 billion in 2015, according to the program's...

  • WASHINGTON— A safeguard for Medicare beneficiaries has become a way for drugmakers to get paid billions of dollars for pricey medications at taxpayer expense, government numbers show. The cost of Medicare's "catastrophic" prescription coverage jumped by 85 percent in three years, from $27.7 billion in 2013 to $51.3 billion in 2015, according to the program's...

  • IT Cosmetics product

    Cosmetics company L'Oreal has agreed to buy IT Cosmetics for $1.2 billion.

  • Regeneron Pharmaceuticals

    Big drug discoveries have been scant, but investors can find long-term value in some biotech names, said Mark Schoenebaum of Evercore ISI.

  • Patrick Swailes Caldwell rehearses his character of “Martin Shkreli” for the Manhattan premiere of the musical “Martin Shkreli’s Game: How Bill Murray Joined the Wu-Tang Clan”

    The campy, song-laden take on the indicted pharmaceutical exec features portrayals of the Wu-Tang Clan, Bill Murray ... and a ghost.

  • July 21- Amgen Inc and Allergan Plc said their copycat version of Roche Holding AG's blockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study. There were no "clinically meaningful" differences in data gathered from patients given Herceptin and the copycat version, ABP 980, to treat a type of early breast cancer, said...

  • July 21- Biogen Inc's quarterly adjusted profit blew past Wall Street estimates on higher sales of its multiple sclerosis drugs, and the company said Chief Executive George Scangos would leave in the coming months. Biogen's hemophilia drugs, Eloctate and Alprolix, posted sales of $125 million and $80 million, respectively, above estimates of $190 million.

  • July 21- Biogen Inc said on Thursday Chief Executive George Scangos will leave the U.S. drugmaker in the coming months and that its board approved a $5 billion share repurchase program. The company said total revenue rose about 12 percent to $2.47 billion in its second-quarter ended June 30. Net income attributable to the company rose to $1.05 billion, or $4.79...

  • NEW YORK— Biogen stock climbed Thursday after the drugmaker reported strong sales of some of its newest treatments for multiple sclerosis and hemophilia. In Thursday morning trading the shares gained $15.92, or 6.1 percent, to $278.33. The company said its net income grew to $1.05 billion, or $4.79 per share.

  • Crucial UK builds effective regulatory system: Roche CEO

    Roche CEO, Severin Schwan explains why the impact of Brexit on the pharmaceutical firm is "rather limited".

  • Very pleased with results: Roche CEO

    Severin Schwan, CEO of Roche, discusses the highlights from the company's earnings results for the first half of 2016.

  • It has been a very good performance: Actelion CEO

    Jean-Paul Clozel, CEO of Actelion, discusses the company's latest earnings results and discusses the pharma sector.